Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 185

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Large-Scale Manufacture and Characterization of a Lentiviral Vector Produced for Clinical Ex Vivo Gene Therapy Application

Merten, Otto-Wilhelm, Charrier, Sabine, Laroudie, Nicolas, Fauchille, Sylvain, Dugué, Céline, Jenny, Christine, Audit, Muriel, Zanta-Boussif, Maria-Antonietta, Chautard, Hélène, Radrizzani, Marina, Vallanti, Giuliana, Naldini, Luigi, Noguiez-Hellin, Patricia, Galy, Anne · 2011 · Human Gene Therapy

Abstract

From the perspective of a pilot clinical gene therapy trial for Wiskott–Aldrich syndrome (WAS), we implemented a process to produce a lentiviral vector under good manufacturing practices (GMP). The process is based on the transient transfection of 293T cells in Cell Factory stacks, scaled up to harvest 50 liters of viral stock per batch, followed by purification of the vesicular stomatitis virus glycoprotein-pseudotyped particles through several membrane-based and chromatographic steps. The process leads to a 200-fold volume concentration and an approximately 3-log reduction in protein and DNA contaminants. An average yield of 13% of infectious particles was obtained in six full-scale preparations. The final product contained low levels of contaminants such as simian virus 40 large T antigen or E1A sequences originating from producer cells. Titers as high as 2 × 109 infectious particles per milliliter were obtained, generating up to 6 × 1011 infectious particles per batch. The purified WAS vector was biologically active, efficiently expressing the genetic insert in WAS protein-deficient B cell lines and transducing CD34+ cells. The vector introduced 0.3–1 vector copy per cell on average in CD34+ cells when used at the concentration of 108 infectious particles per milliliter, which is comparable to preclinical preparations. There was no evidence of cellular toxicity. These results show the implementation of large-scale GMP production, purification, and control of advanced HIV-1-derived lentiviral technology. Results obtained with the WAS vector provide the initial manufacturing and quality control benchmarking that should be helpful to further development and clinical applications. Merten et al. describe a large scale (50 liter) method for the production of recombinant lentiviral vectors with extensive purification steps using membrane-based techniques, ion-exchange chromatography, and gel-filtration chromatography. This process was used to produce vector for a clinical trial in patients with Wiskott—Aldrich syndrome. Characterization of the batches produced under GMP conditions, evaluation of their in vitro functionality, and some key safety parameters of the lentiviral vector batches are presented in this methods article.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/hum.2010.060

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

Metadata

Authors
Merten, O.-W., Charrier, S., Laroudie, N., Fauchille, S., Dugué, C., Jenny, C., Audit, M., Zanta-Boussif, M.-A., Chautard, H., Radrizzani, M., Vallanti, G., Naldini, L., Noguiez-Hellin, P., & Galy, A.
Venue
Human Gene Therapy
Published
2011-03
Volume
22
Issue
3
Pages
343-356
ISSN
  • 1043-0342 (ISSN-L)
  • 1557-7422
OpenAlex
W2106053795
Cited by
185
References
6
FWCI
6.71
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.